| Reagan-Udall Foundation

Each year, the Reagan-Udall Foundation for the FDA conducts an Annual Public Meeting of its Board of Directors to share its activities in support of the U.S. Food and Drug Administration. This free virtual meeting is open to the public, but advanced registration is required.

Events

Read more about 2021 Annual Public Meeting

The FDA Foundation Research Program works to accelerate and improve the availability of safe and effective medical products.

Research & Analysis

Read more about Research

The Expanded Access Navigator, or EA Navigator, represents a unique partnership between the Reagan-Udall Foundation for the FDA, patient advocacy organizations, the pharmaceutical industry, and the federal government to provide clear, digestible information on single-patient EA.

Learn More

Patient, Provider & Consumer Services

Read more about Expanded Access Navigator

Read more about A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Read more about The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease

Read more about A Study on the Effectiveness of Ankle Dorsiflexion Range of Motion Training in Patients With Patellofemoral Joint Pain.

Read more about Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Radiation, and Checkpoint Inhibitors

Read more about ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

In 2023, the Reagan-Udall Foundation published plans for a public private partnership with industry to voluntarily collect data on the use of antimicrobials in farm animals.

Coverage

Read more about U.S. Right to Know: FDA layoffs will hamper efforts to cut antimicrobial overuse in farm animals

Zeroing in on what is needed to improve operations, including the PMTA process, Booth said a review of the Reagan-Udall Foundation report is critical.

Coverage

Read more about CSP Daily News: After Mass Layoffs at the FDA's Center for Tobacco Products, What Happens Next?

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Subscribe for updates from the Reagan-Udall Foundation for the FDA